[1]
Chan JF,To KK,Tse H,Jin DY,Yuen KY, Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends in microbiology. 2013 Oct; [PubMed PMID: 23770275]
[2]
Lei J,Kusov Y,Hilgenfeld R, Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antiviral research. 2018 Jan [PubMed PMID: 29128390]
[3]
Chan JF,Kok KH,Zhu Z,Chu H,To KK,Yuan S,Yuen KY, Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes [PubMed PMID: 31987001]
[4]
Biryukov J,Boydston JA,Dunning RA,Yeager JJ,Wood S,Ferris A,Miller D,Weaver W,Zeitouni NE,Freeburger D,Dabisch P,Wahl V,Hevey MC,Altamura LA, SARS-CoV-2 is rapidly inactivated at high temperature. Environmental chemistry letters. 2021 Feb 3; [PubMed PMID: 33551702]
[5]
Andersen KG,Rambaut A,Lipkin WI,Holmes EC,Garry RF, The proximal origin of SARS-CoV-2. Nature medicine. 2020 Apr [PubMed PMID: 32284615]
[6]
Zhang T,Wu Q,Zhang Z, Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Current biology : CB. 2020 Apr 6 [PubMed PMID: 32197085]
[7]
Oreshkova N,Molenaar RJ,Vreman S,Harders F,Oude Munnink BB,Hakze-van der Honing RW,Gerhards N,Tolsma P,Bouwstra R,Sikkema RS,Tacken MG,de Rooij MM,Weesendorp E,Engelsma MY,Bruschke CJ,Smit LA,Koopmans M,van der Poel WH,Stegeman A, SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020 Jun [PubMed PMID: 32553059]
[8]
Korber B,Fischer WM,Gnanakaran S,Yoon H,Theiler J,Abfalterer W,Hengartner N,Giorgi EE,Bhattacharya T,Foley B,Hastie KM,Parker MD,Partridge DG,Evans CM,Freeman TM,de Silva TI,Sheffield COVID-19 Genomics Group.,McDanal C,Perez LG,Tang H,Moon-Walker A,Whelan SP,LaBranche CC,Saphire EO,Montefiori DC, Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020 Aug 20 [PubMed PMID: 32697968]
[9]
Galloway SE,Paul P,MacCannell DR,Johansson MA,Brooks JT,MacNeil A,Slayton RB,Tong S,Silk BJ,Armstrong GL,Biggerstaff M,Dugan VG, Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. MMWR. Morbidity and mortality weekly report. 2021 Jan 22 [PubMed PMID: 33476315]
[10]
Volz E,Mishra S,Chand M,Barrett JC,Johnson R,Geidelberg L,Hinsley WR,Laydon DJ,Dabrera G,O'Toole Á,Amato R,Ragonnet-Cronin M,Harrison I,Jackson B,Ariani CV,Boyd O,Loman NJ,McCrone JT,Gonçalves S,Jorgensen D,Myers R,Hill V,Jackson DK,Gaythorpe K,Groves N,Sillitoe J,Kwiatkowski DP,COVID-19 Genomics UK (COG-UK) consortium.,Flaxman S,Ratmann O,Bhatt S,Hopkins S,Gandy A,Rambaut A,Ferguson NM, Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021 Mar 25 [PubMed PMID: 33767447]
[11]
Wu K,Werner AP,Moliva JI,Koch M,Choi A,Stewart-Jones GBE,Bennett H,Boyoglu-Barnum S,Shi W,Graham BS,Carfi A,Corbett KS,Seder RA,Edwards DK, mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv : the preprint server for biology. 2021 Jan 25 [PubMed PMID: 33501442]
[12]
Davies NG,Abbott S,Barnard RC,Jarvis CI,Kucharski AJ,Munday JD,Pearson CAB,Russell TW,Tully DC,Washburne AD,Wenseleers T,Gimma A,Waites W,Wong KLM,van Zandvoort K,Silverman JD,CMMID COVID-19 Working Group.,COVID-19 Genomics UK (COG-UK) Consortium.,Diaz-Ordaz K,Keogh R,Eggo RM,Funk S,Jit M,Atkins KE,Edmunds WJ, Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (New York, N.Y.). 2021 Apr 9 [PubMed PMID: 33658326]
[13]
Walensky RP,Walke HT,Fauci AS, SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities. JAMA. 2021 Mar 16 [PubMed PMID: 33595644]
[14]
Davies NG,Barnard RC,Jarvis CI,Russell TW,Semple MG,Jit M,Edmunds WJ,Centre for Mathematical Modelling of Infectious Diseases COVID-19 Working Group.,ISARIC4C investigators., Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study. The Lancet. Infectious diseases. 2021 Apr [PubMed PMID: 33357518]
[15]
Challen R,Brooks-Pollock E,Read JM,Dyson L,Tsaneva-Atanasova K,Danon L, Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ (Clinical research ed.). 2021 Mar 9 [PubMed PMID: 33687922]
[16]
Davies NG,Jarvis CI,CMMID COVID-19 Working Group.,Edmunds WJ,Jewell NP,Diaz-Ordaz K,Keogh RH, Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021 Mar 15 [PubMed PMID: 33723411]
[17]
Grint DJ,Wing K,Williamson E,McDonald HI,Bhaskaran K,Evans D,Evans SJ,Walker AJ,Hickman G,Nightingale E,Schultze A,Rentsch CT,Bates C,Cockburn J,Curtis HJ,Morton CE,Bacon S,Davy S,Wong AY,Mehrkar A,Tomlinson L,Douglas IJ,Mathur R,Blomquist P,MacKenna B,Ingelsby P,Croker R,Parry J,Hester F,Harper S,DeVito NJ,Hulme W,Tazare J,Goldacre B,Smeeth L,Eggo RM, Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2021 Mar [PubMed PMID: 33739254]
[18]
Tegally H,Wilkinson E,Giovanetti M,Iranzadeh A,Fonseca V,Giandhari J,Doolabh D,Pillay S,San EJ,Msomi N,Mlisana K,von Gottberg A,Walaza S,Allam M,Ismail A,Mohale T,Glass AJ,Engelbrecht S,Van Zyl G,Preiser W,Petruccione F,Sigal A,Hardie D,Marais G,Hsiao NY,Korsman S,Davies MA,Tyers L,Mudau I,York D,Maslo C,Goedhals D,Abrahams S,Laguda-Akingba O,Alisoltani-Dehkordi A,Godzik A,Wibmer CK,Sewell BT,Lourenço J,Alcantara LCJ,Kosakovsky Pond SL,Weaver S,Martin D,Lessells RJ,Bhiman JN,Williamson C,de Oliveira T, Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021 Apr [PubMed PMID: 33690265]
[19]
Wibmer CK,Ayres F,Hermanus T,Madzivhandila M,Kgagudi P,Oosthuysen B,Lambson BE,de Oliveira T,Vermeulen M,van der Berg K,Rossouw T,Boswell M,Ueckermann V,Meiring S,von Gottberg A,Cohen C,Morris L,Bhiman JN,Moore PL, SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv : the preprint server for biology. 2021 Jan 19 [PubMed PMID: 33501446]
[20]
Mwenda M,Saasa N,Sinyange N,Busby G,Chipimo PJ,Hendry J,Kapona O,Yingst S,Hines JZ,Minchella P,Simulundu E,Changula K,Nalubamba KS,Sawa H,Kajihara M,Yamagishi J,Kapin'a M,Kapata N,Fwoloshi S,Zulu P,Mulenga LB,Agolory S,Mukonka V,Bridges DJ, Detection of B.1.351 SARS-CoV-2 Variant Strain - Zambia, December 2020. MMWR. Morbidity and mortality weekly report. 2021 Feb 26 [PubMed PMID: 33630820]
[21]
Wang P,Wang M,Yu J,Cerutti G,Nair MS,Huang Y,Kwong PD,Shapiro L,Ho DD, Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. bioRxiv : the preprint server for biology. 2021 Mar 2 [PubMed PMID: 33688656]
[22]
Faria NR,Mellan TA,Whittaker C,Claro IM,Candido DDS,Mishra S,Crispim MAE,Sales FC,Hawryluk I,McCrone JT,Hulswit RJG,Franco LAM,Ramundo MS,de Jesus JG,Andrade PS,Coletti TM,Ferreira GM,Silva CAM,Manuli ER,Pereira RHM,Peixoto PS,Kraemer MU,Gaburo N,Camilo CDC,Hoeltgebaum H,Souza WM,Rocha EC,de Souza LM,de Pinho MC,Araujo LJT,Malta FSV,de Lima AB,Silva JDP,Zauli DAG,Ferreira ACS,Schnekenberg RP,Laydon DJ,Walker PGT,Schlüter HM,Dos Santos ALP,Vidal MS,Del Caro VS,Filho RMF,Dos Santos HM,Aguiar RS,Modena JLP,Nelson B,Hay JA,Monod M,Miscouridou X,Coupland H,Sonabend R,Vollmer M,Gandy A,Suchard MA,Bowden TA,Pond SLK,Wu CH,Ratmann O,Ferguson NM,Dye C,Loman NJ,Lemey P,Rambaut A,Fraiji NA,Carvalho MDPSS,Pybus OG,Flaxman S,Bhatt S,Sabino EC, Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv : the preprint server for health sciences. 2021 Mar 3 [PubMed PMID: 33688664]
[25]
Gu H,Krishnan P,Ng DYM,Chang LDJ,Liu GYZ,Cheng SSM,Hui MMY,Fan MCY,Wan JHL,Lau LHK,Cowling BJ,Peiris M,Poon LLM, Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel, Hong Kong, China, November 2021. Emerging infectious diseases. 2021 Dec 3; [PubMed PMID: 34860154]
[26]
Chen J,Wang R,Gilby NB,Wei GW, Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. ArXiv. 2021 Dec 1; [PubMed PMID: 34873578]
[27]
Zhang W,Davis BD,Chen SS,Sincuir Martinez JM,Plummer JT,Vail E, Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA. 2021 Apr 6 [PubMed PMID: 33571356]
[28]
van Doremalen N,Bushmaker T,Morris DH,Holbrook MG,Gamble A,Williamson BN,Tamin A,Harcourt JL,Thornburg NJ,Gerber SI,Lloyd-Smith JO,de Wit E,Munster VJ, Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. The New England journal of medicine. 2020 Apr 16 [PubMed PMID: 32182409]
[29]
Riddell S,Goldie S,Hill A,Eagles D,Drew TW, The effect of temperature on persistence of SARS-CoV-2 on common surfaces. Virology journal. 2020 Oct 7 [PubMed PMID: 33028356]
[30]
Guo ZD,Wang ZY,Zhang SF,Li X,Li L,Li C,Cui Y,Fu RB,Dong YZ,Chi XY,Zhang MY,Liu K,Cao C,Liu B,Zhang K,Gao YW,Lu B,Chen W, Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. Emerging infectious diseases. 2020 Apr 10 [PubMed PMID: 32275497]
[31]
Yeo C,Kaushal S,Yeo D, Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? The lancet. Gastroenterology & hepatology. 2020 Apr [PubMed PMID: 32087098]
[32]
Kotlyar AM,Grechukhina O,Chen A,Popkhadze S,Grimshaw A,Tal O,Taylor HS,Tal R, Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. American journal of obstetrics and gynecology. 2021 Jan [PubMed PMID: 32739398]
[33]
Ahmad FB,Cisewski JA,Miniño A,Anderson RN, Provisional Mortality Data - United States, 2020. MMWR. Morbidity and mortality weekly report. 2021 Apr 9 [PubMed PMID: 33830988]
[34]
Stokes EK,Zambrano LD,Anderson KN,Marder EP,Raz KM,El Burai Felix S,Tie Y,Fullerton KE, Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR. Morbidity and mortality weekly report. 2020 Jun 19 [PubMed PMID: 32555134]
[35]
Gebhard C,Regitz-Zagrosek V,Neuhauser HK,Morgan R,Klein SL, Impact of sex and gender on COVID-19 outcomes in Europe. Biology of sex differences. 2020 May 25 [PubMed PMID: 32450906]
[36]
Jin JM,Bai P,He W,Wu F,Liu XF,Han DM,Liu S,Yang JK, Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Frontiers in public health. 2020 [PubMed PMID: 32411652]
[37]
Finelli L,Gupta V,Petigara T,Yu K,Bauer KA,Puzniak LA, Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020. JAMA network open. 2021 Apr 1 [PubMed PMID: 33830226]
[38]
Romano SD,Blackstock AJ,Taylor EV,El Burai Felix S,Adjei S,Singleton CM,Fuld J,Bruce BB,Boehmer TK, Trends in Racial and Ethnic Disparities in COVID-19 Hospitalizations, by Region - United States, March-December 2020. MMWR. Morbidity and mortality weekly report. 2021 Apr 16 [PubMed PMID: 33857068]
[39]
Sze S,Pan D,Nevill CR,Gray LJ,Martin CA,Nazareth J,Minhas JS,Divall P,Khunti K,Abrams KR,Nellums LB,Pareek M, Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2020 Dec [PubMed PMID: 33200120]
[40]
Heslin KC,Hall JE, Sexual Orientation Disparities in Risk Factors for Adverse COVID-19-Related Outcomes, by Race/Ethnicity - Behavioral Risk Factor Surveillance System, United States, 2017-2019. MMWR. Morbidity and mortality weekly report. 2021 Feb 5 [PubMed PMID: 33539330]
[41]
Song W,Gui M,Wang X,Xiang Y, Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS pathogens. 2018 Aug [PubMed PMID: 30102747]
[42]
Jiang S,Hillyer C,Du L, Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355-359; 2020). Trends in immunology. 2020 Jun [PubMed PMID: 32362491]
[43]
Du L,He Y,Zhou Y,Liu S,Zheng BJ,Jiang S, The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nature reviews. Microbiology. 2009 Mar [PubMed PMID: 19198616]
[44]
Jiang S,Hillyer C,Du L, Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends in immunology. 2020 May [PubMed PMID: 32249063]
[45]
de Abajo FJ,Rodríguez-Martín S,Lerma V,Mejía-Abril G,Aguilar M,García-Luque A,Laredo L,Laosa O,Centeno-Soto GA,Ángeles Gálvez M,Puerro M,González-Rojano E,Pedraza L,de Pablo I,Abad-Santos F,Rodríguez-Mañas L,Gil M,Tobías A,Rodríguez-Miguel A,Rodríguez-Puyol D, Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet (London, England). 2020 May 30 [PubMed PMID: 32416785]
[46]
Xu H,Zhong L,Deng J,Peng J,Dan H,Zeng X,Li T,Chen Q, High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International journal of oral science. 2020 Feb 24 [PubMed PMID: 32094336]
[47]
Hoffmann M,Kleine-Weber H,Schroeder S,Krüger N,Herrler T,Erichsen S,Schiergens TS,Herrler G,Wu NH,Nitsche A,Müller MA,Drosten C,Pöhlmann S, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16 [PubMed PMID: 32142651]
[48]
Wang J,Jiang M,Chen X,Montaner LJ, Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. Journal of leukocyte biology. 2020 Jul [PubMed PMID: 32534467]
[49]
Azkur AK,Akdis M,Azkur D,Sokolowska M,van de Veen W,Brüggen MC,O'Mahony L,Gao Y,Nadeau K,Akdis CA, Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020 Jul [PubMed PMID: 32396996]
[50]
Teuwen LA,Geldhof V,Pasut A,Carmeliet P, COVID-19: the vasculature unleashed. Nature reviews. Immunology. 2020 Jul [PubMed PMID: 32439870]
[51]
Ackermann M,Verleden SE,Kuehnel M,Haverich A,Welte T,Laenger F,Vanstapel A,Werlein C,Stark H,Tzankov A,Li WW,Li VW,Mentzer SJ,Jonigk D, Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. The New England journal of medicine. 2020 Jul 9 [PubMed PMID: 32437596]
[52]
van de Veerdonk FL,Netea MG,van Deuren M,van der Meer JW,de Mast Q,Brüggemann RJ,van der Hoeven H, Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife. 2020 Apr 27 [PubMed PMID: 32338605]
[53]
Conti P,Ronconi G,Caraffa A,Gallenga CE,Ross R,Frydas I,Kritas SK, Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. Journal of biological regulators and homeostatic agents. 2020 Mar 14 [PubMed PMID: 32171193]
[54]
Coopersmith CM,Antonelli M,Bauer SR,Deutschman CS,Evans LE,Ferrer R,Hellman J,Jog S,Kesecioglu J,Kissoon N,Martin-Loeches I,Nunnally ME,Prescott HC,Rhodes A,Talmor D,Tissieres P,De Backer D, The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Critical care medicine. 2021 Apr 1 [PubMed PMID: 33591008]
[55]
Huang C,Wang Y,Li X,Ren L,Zhao J,Hu Y,Zhang L,Fan G,Xu J,Gu X,Cheng Z,Yu T,Xia J,Wei Y,Wu W,Xie X,Yin W,Li H,Liu M,Xiao Y,Gao H,Guo L,Xie J,Wang G,Jiang R,Gao Z,Jin Q,Wang J,Cao B, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020 Feb 15; [PubMed PMID: 31986264]
[56]
Liu H,Wei P,Zhang Q,Chen Z,Aviszus K,Downing W,Peterson S,Reynoso L,Downey GP,Frankel SK,Kappler J,Marrack P,Zhang G, 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab {i}in vitro{/i}. bioRxiv : the preprint server for biology. 2021 Feb 16 [PubMed PMID: 33619479]
[57]
Hua A,O'Gallagher K,Sado D,Byrne J, Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. European heart journal. 2020 Jun 7 [PubMed PMID: 32227076]
[58]
Guo T,Fan Y,Chen M,Wu X,Zhang L,He T,Wang H,Wan J,Wang X,Lu Z, Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA cardiology. 2020 Jul 1 [PubMed PMID: 32219356]
[59]
Libby P,Loscalzo J,Ridker PM,Farkouh ME,Hsue PY,Fuster V,Hasan AA,Amar S, Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2018 Oct 23 [PubMed PMID: 30336831]
[60]
Tan L,Wang Q,Zhang D,Ding J,Huang Q,Tang YQ,Wang Q,Miao H, Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal transduction and targeted therapy. 2020 Mar 27 [PubMed PMID: 32296069]
[61]
Abou-Ismail MY,Diamond A,Kapoor S,Arafah Y,Nayak L, The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thrombosis research. 2020 Oct [PubMed PMID: 32788101]
[62]
Amgalan A,Othman M, Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered questions. Journal of thrombosis and haemostasis : JTH. 2020 Jun [PubMed PMID: 32278338]
[63]
Ni W,Yang X,Yang D,Bao J,Li R,Xiao Y,Hou C,Wang H,Liu J,Yang D,Xu Y,Cao Z,Gao Z, Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical care (London, England). 2020 Jul 13 [PubMed PMID: 32660650]
[64]
Zubair AS,McAlpine LS,Gardin T,Farhadian S,Kuruvilla DE,Spudich S, Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA neurology. 2020 Aug 1 [PubMed PMID: 32469387]
[65]
Patel KP,Patel PA,Vunnam RR,Hewlett AT,Jain R,Jing R,Vunnam SR, Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2020 Jul [PubMed PMID: 32388469]
[66]
Aleem A,Shah H, Gastrointestinal And Hepatic Manifestations Of Coronavirus (COVID-19) StatPearls. 2021 Jan [PubMed PMID: 34033324]
[67]
Gabarre P,Dumas G,Dupont T,Darmon M,Azoulay E,Zafrani L, Acute kidney injury in critically ill patients with COVID-19. Intensive care medicine. 2020 Jul [PubMed PMID: 32533197]
[68]
Ziemba R,Campbell KN,Yang TH,Schaeffer SE,Mayo KM,McGann P,Quinn S,Roach J,Huff ED, Excess Death Estimates in Patients with End-Stage Renal Disease - United States, February-August 2020. MMWR. Morbidity and mortality weekly report. 2021 Jun 4 [PubMed PMID: 34081687]
[69]
Chi X,Yan R,Zhang J,Zhang G,Zhang Y,Hao M,Zhang Z,Fan P,Dong Y,Yang Y,Chen Z,Guo Y,Zhang J,Li Y,Song X,Chen Y,Xia L,Fu L,Hou L,Xu J,Yu C,Li J,Zhou Q,Chen W, A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science (New York, N.Y.). 2020 Aug 7 [PubMed PMID: 32571838]
[70]
Liu H,Zhang Q,Wei P,Chen Z,Aviszus K,Yang J,Downing W,Peterson S,Jiang C,Liang B,Reynoso L,Downey GP,Frankel SK,Kappler J,Marrack P,Zhang G, The basis of a more contagious 501Y.V1 variant of SARS-COV-2. bioRxiv : the preprint server for biology. 2021 Feb 2 [PubMed PMID: 33564771]
[71]
Borczuk AC,Salvatore SP,Seshan SV,Patel SS,Bussel JB,Mostyka M,Elsoukkary S,He B,Del Vecchio C,Fortarezza F,Pezzuto F,Navalesi P,Crisanti A,Fowkes ME,Bryce CH,Calabrese F,Beasley MB, COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2020 Nov [PubMed PMID: 32879413]
[72]
Solomon IH,Normandin E,Bhattacharyya S,Mukerji SS,Keller K,Ali AS,Adams G,Hornick JL,Padera RF Jr,Sabeti P, Neuropathological Features of Covid-19. The New England journal of medicine. 2020 Sep 3 [PubMed PMID: 32530583]
[73]
Lindner D,Fitzek A,Bräuninger H,Aleshcheva G,Edler C,Meissner K,Scherschel K,Kirchhof P,Escher F,Schultheiss HP,Blankenberg S,Püschel K,Westermann D, Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA cardiology. 2020 Nov 1 [PubMed PMID: 32730555]
[74]
Su H,Yang M,Wan C,Yi LX,Tang F,Zhu HY,Yi F,Yang HC,Fogo AB,Nie X,Zhang C, Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney international. 2020 Jul [PubMed PMID: 32327202]
[75]
Lin L,Jiang X,Zhang Z,Huang S,Zhang Z,Fang Z,Gu Z,Gao L,Shi H,Mai L,Liu Y,Lin X,Lai R,Yan Z,Li X,Shan H, Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020 Jun [PubMed PMID: 32241899]
[76]
Lax SF,Skok K,Zechner P,Kessler HH,Kaufmann N,Koelblinger C,Vander K,Bargfrieder U,Trauner M, Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective, Single-Center, Clinicopathologic Case Series. Annals of internal medicine. 2020 Sep 1 [PubMed PMID: 32422076]
[77]
Lauer SA,Grantz KH,Bi Q,Jones FK,Zheng Q,Meredith HR,Azman AS,Reich NG,Lessler J, The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of internal medicine. 2020 May 5 [PubMed PMID: 32150748]
[78]
Mizumoto K,Kagaya K,Zarebski A,Chowell G, Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020 Mar [PubMed PMID: 32183930]
[79]
Nishiura H,Kobayashi T,Miyama T,Suzuki A,Jung SM,Hayashi K,Kinoshita R,Yang Y,Yuan B,Akhmetzhanov AR,Linton NM, Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020 May [PubMed PMID: 32179137]
[80]
Zhu J,Zhong Z,Ji P,Li H,Li B,Pang J,Zhang J,Zhao C, Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Family medicine and community health. 2020 Apr [PubMed PMID: 32371463]
[81]
Li J,Huang DQ,Zou B,Yang H,Hui WZ,Rui F,Yee NTS,Liu C,Nerurkar SN,Kai JCY,Teng MLP,Li X,Zeng H,Borghi JA,Henry L,Cheung R,Nguyen MH, Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. Journal of medical virology. 2021 Mar [PubMed PMID: 32790106]
[82]
Yang AP,Liu JP,Tao WQ,Li HM, The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. International immunopharmacology. 2020 Jul [PubMed PMID: 32304994]
[83]
ARDS Definition Task Force.,Ranieri VM,Rubenfeld GD,Thompson BT,Ferguson ND,Caldwell E,Fan E,Camporota L,Slutsky AS, Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20 [PubMed PMID: 22797452]
[84]
Ferrando C,Suarez-Sipmann F,Mellado-Artigas R,Hernández M,Gea A,Arruti E,Aldecoa C,Martínez-Pallí G,Martínez-González MA,Slutsky AS,Villar J,COVID-19 Spanish ICU Network., Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. Intensive care medicine. 2020 Dec [PubMed PMID: 32728965]
[85]
Martinez-Rojas MA,Vega-Vega O,Bobadilla NA, Is the kidney a target of SARS-CoV-2? American journal of physiology. Renal physiology. 2020 Jun 1 [PubMed PMID: 32412303]
[86]
Hirsch JS,Ng JH,Ross DW,Sharma P,Shah HH,Barnett RL,Hazzan AD,Fishbane S,Jhaveri KD,Northwell COVID-19 Research Consortium.,Northwell Nephrology COVID-19 Research Consortium., Acute kidney injury in patients hospitalized with COVID-19. Kidney international. 2020 Jul [PubMed PMID: 32416116]
[87]
Gupta A,Madhavan MV,Sehgal K,Nair N,Mahajan S,Sehrawat TS,Bikdeli B,Ahluwalia N,Ausiello JC,Wan EY,Freedberg DE,Kirtane AJ,Parikh SA,Maurer MS,Nordvig AS,Accili D,Bathon JM,Mohan S,Bauer KA,Leon MB,Krumholz HM,Uriel N,Mehra MR,Elkind MSV,Stone GW,Schwartz A,Ho DD,Bilezikian JP,Landry DW, Extrapulmonary manifestations of COVID-19. Nature medicine. 2020 Jul [PubMed PMID: 32651579]
[88]
Hessami A,Shamshirian A,Heydari K,Pourali F,Alizadeh-Navaei R,Moosazadeh M,Abrotan S,Shojaie L,Sedighi S,Shamshirian D,Rezaei N, Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. The American journal of emergency medicine. 2020 Oct 16 [PubMed PMID: 33268238]
[89]
Tariq R,Saha S,Furqan F,Hassett L,Pardi D,Khanna S, Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. Mayo Clinic proceedings. 2020 Aug [PubMed PMID: 32753138]
[90]
Azouz E,Yang S,Monnier-Cholley L,Arrivé L, Systemic arterial thrombosis and acute mesenteric ischemia in a patient with COVID-19. Intensive care medicine. 2020 Jul [PubMed PMID: 32424482]
[91]
Xu L,Liu J,Lu M,Yang D,Zheng X, Liver injury during highly pathogenic human coronavirus infections. Liver international : official journal of the International Association for the Study of the Liver. 2020 May [PubMed PMID: 32170806]
[92]
Toscano G,Palmerini F,Ravaglia S,Ruiz L,Invernizzi P,Cuzzoni MG,Franciotta D,Baldanti F,Daturi R,Postorino P,Cavallini A,Micieli G, Guillain-Barré Syndrome Associated with SARS-CoV-2. The New England journal of medicine. 2020 Jun 25 [PubMed PMID: 32302082]
[93]
Daneshgaran G,Dubin DP,Gould DJ, Cutaneous Manifestations of COVID-19: An Evidence-Based Review. American journal of clinical dermatology. 2020 Oct [PubMed PMID: 32865778]
[94]
Wiersinga WJ,Rhodes A,Cheng AC,Peacock SJ,Prescott HC, Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Aug 25 [PubMed PMID: 32648899]
[97]
Jayk Bernal A,Gomes da Silva MM,Musungaie DB,Kovalchuk E,Gonzalez A,Delos Reyes V,Martín-Quirós A,Caraco Y,Williams-Diaz A,Brown ML,Du J,Pedley A,Assaid C,Strizki J,Grobler JA,Shamsuddin HH,Tipping R,Wan H,Paschke A,Butterton JR,Johnson MG,De Anda C,MOVe-OUT Study Group., Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. The New England journal of medicine. 2021 Dec 16; [PubMed PMID: 34914868]
[98]
Mahase E, Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ (Clinical research ed.). 2021 Nov 8; [PubMed PMID: 34750163]
[99]
Wang M,Cao R,Zhang L,Yang X,Liu J,Xu M,Shi Z,Hu Z,Zhong W,Xiao G, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020 Mar [PubMed PMID: 32020029]
[100]
Beigel JH,Tomashek KM,Dodd LE,Mehta AK,Zingman BS,Kalil AC,Hohmann E,Chu HY,Luetkemeyer A,Kline S,Lopez de Castilla D,Finberg RW,Dierberg K,Tapson V,Hsieh L,Patterson TF,Paredes R,Sweeney DA,Short WR,Touloumi G,Lye DC,Ohmagari N,Oh MD,Ruiz-Palacios GM,Benfield T,Fätkenheuer G,Kortepeter MG,Atmar RL,Creech CB,Lundgren J,Babiker AG,Pett S,Neaton JD,Burgess TH,Bonnett T,Green M,Makowski M,Osinusi A,Nayak S,Lane HC,ACTT-1 Study Group Members., Remdesivir for the Treatment of Covid-19 - Final Report. The New England journal of medicine. 2020 Nov 5 [PubMed PMID: 32445440]
[101]
Goldman JD,Lye DCB,Hui DS,Marks KM,Bruno R,Montejano R,Spinner CD,Galli M,Ahn MY,Nahass RG,Chen YS,SenGupta D,Hyland RH,Osinusi AO,Cao H,Blair C,Wei X,Gaggar A,Brainard DM,Towner WJ,Muñoz J,Mullane KM,Marty FM,Tashima KT,Diaz G,Subramanian A,GS-US-540-5773 Investigators., Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. The New England journal of medicine. 2020 Nov 5 [PubMed PMID: 32459919]
[102]
Spinner CD,Gottlieb RL,Criner GJ,Arribas López JR,Cattelan AM,Soriano Viladomiu A,Ogbuagu O,Malhotra P,Mullane KM,Castagna A,Chai LYA,Roestenberg M,Tsang OTY,Bernasconi E,Le Turnier P,Chang SC,SenGupta D,Hyland RH,Osinusi AO,Cao H,Blair C,Wang H,Gaggar A,Brainard DM,McPhail MJ,Bhagani S,Ahn MY,Sanyal AJ,Huhn G,Marty FM,GS-US-540-5774 Investigators., Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 Sep 15 [PubMed PMID: 32821939]
[103]
Zhang R,Mylonakis E, In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality. Annals of internal medicine. 2021 Feb [PubMed PMID: 33524282]
[104]
Gottlieb RL,Vaca CE,Paredes R,Mera J,Webb BJ,Perez G,Oguchi G,Ryan P,Nielsen BU,Brown M,Hidalgo A,Sachdeva Y,Mittal S,Osiyemi O,Skarbinski J,Juneja K,Hyland RH,Osinusi A,Chen S,Camus G,Abdelghany M,Davies S,Behenna-Renton N,Duff F,Marty FM,Katz MJ,Ginde AA,Brown SM,Schiffer JT,Hill JA,GS-US-540-9012 (PINETREE) Investigators., Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. The New England journal of medicine. 2021 Dec 22; [PubMed PMID: 34937145]
[105]
RECOVERY Collaborative Group.,Horby P,Mafham M,Linsell L,Bell JL,Staplin N,Emberson JR,Wiselka M,Ustianowski A,Elmahi E,Prudon B,Whitehouse T,Felton T,Williams J,Faccenda J,Underwood J,Baillie JK,Chappell LC,Faust SN,Jaki T,Jeffery K,Lim WS,Montgomery A,Rowan K,Tarning J,Watson JA,White NJ,Juszczak E,Haynes R,Landray MJ, Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England journal of medicine. 2020 Nov 19 [PubMed PMID: 33031652]
[106]
Mitjà O,Corbacho-Monné M,Ubals M,Alemany A,Suñer C,Tebé C,Tobias A,Peñafiel J,Ballana E,Pérez CA,Admella P,Riera-Martí N,Laporte P,Mitjà J,Clua M,Bertran L,Sarquella M,Gavilán S,Ara J,Argimon JM,Cuatrecasas G,Cañadas P,Elizalde-Torrent A,Fabregat R,Farré M,Forcada A,Flores-Mateo G,López C,Muntada E,Nadal N,Narejos S,Nieto A,Prat N,Puig J,Quiñones C,Ramírez-Viaplana F,Reyes-Urueña J,Riveira-Muñoz E,Ruiz L,Sanz S,Sentís A,Sierra A,Velasco C,Vivanco-Hidalgo RM,Zamora J,Casabona J,Vall-Mayans M,González-Beiras C,Clotet B,BCN-PEP-CoV2 Research Group., A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. The New England journal of medicine. 2021 Feb 4 [PubMed PMID: 33289973]
[107]
Boulware DR,Pullen MF,Bangdiwala AS,Pastick KA,Lofgren SM,Okafor EC,Skipper CP,Nascene AA,Nicol MR,Abassi M,Engen NW,Cheng MP,LaBar D,Lother SA,MacKenzie LJ,Drobot G,Marten N,Zarychanski R,Kelly LE,Schwartz IS,McDonald EG,Rajasingham R,Lee TC,Hullsiek KH, A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. The New England journal of medicine. 2020 Aug 6 [PubMed PMID: 32492293]
[108]
Cao B,Wang Y,Wen D,Liu W,Wang J,Fan G,Ruan L,Song B,Cai Y,Wei M,Li X,Xia J,Chen N,Xiang J,Yu T,Bai T,Xie X,Zhang L,Li C,Yuan Y,Chen H,Li H,Huang H,Tu S,Gong F,Liu Y,Wei Y,Dong C,Zhou F,Gu X,Xu J,Liu Z,Zhang Y,Li H,Shang L,Wang K,Li K,Zhou X,Dong X,Qu Z,Lu S,Hu X,Ruan S,Luo S,Wu J,Peng L,Cheng F,Pan L,Zou J,Jia C,Wang J,Liu X,Wang S,Wu X,Ge Q,He J,Zhan H,Qiu F,Guo L,Huang C,Jaki T,Hayden FG,Horby PW,Zhang D,Wang C, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England journal of medicine. 2020 May 7 [PubMed PMID: 32187464]
[109]
Caly L,Druce JD,Catton MG,Jans DA,Wagstaff KM, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research. 2020 Jun [PubMed PMID: 32251768]
[110]
López-Medina E,López P,Hurtado IC,Dávalos DM,Ramirez O,Martínez E,Díazgranados JA,Oñate JM,Chavarriaga H,Herrera S,Parra B,Libreros G,Jaramillo R,Avendaño AC,Toro DF,Torres M,Lesmes MC,Rios CA,Caicedo I, Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021 Apr 13 [PubMed PMID: 33662102]
[111]
Joyner MJ,Senefeld JW,Klassen SA,Mills JR,Johnson PW,Theel ES,Wiggins CC,Bruno KA,Klompas AM,Lesser ER,Kunze KL,Sexton MA,Diaz Soto JC,Baker SE,Shepherd JRA,van Helmond N,van Buskirk CM,Winters JL,Stubbs JR,Rea RF,Hodge DO,Herasevich V,Whelan ER,Clayburn AJ,Larson KF,Ripoll JG,Andersen KJ,Buras MR,Vogt MNP,Dennis JJ,Regimbal RJ,Bauer PR,Blair JE,Paneth NS,Fairweather D,Wright RS,Carter RE,Casadevall A, Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv : the preprint server for health sciences. 2020 Aug 12 [PubMed PMID: 32817978]
[112]
Joyner MJ,Bruno KA,Klassen SA,Kunze KL,Johnson PW,Lesser ER,Wiggins CC,Senefeld JW,Klompas AM,Hodge DO,Shepherd JRA,Rea RF,Whelan ER,Clayburn AJ,Spiegel MR,Baker SE,Larson KF,Ripoll JG,Andersen KJ,Buras MR,Vogt MNP,Herasevich V,Dennis JJ,Regimbal RJ,Bauer PR,Blair JE,van Buskirk CM,Winters JL,Stubbs JR,van Helmond N,Butterfield BP,Sexton MA,Diaz Soto JC,Paneth NS,Verdun NC,Marks P,Casadevall A,Fairweather D,Carter RE,Wright RS, Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. Mayo Clinic proceedings. 2020 Sep [PubMed PMID: 32861333]
[113]
Simonovich VA,Burgos Pratx LD,Scibona P,Beruto MV,Vallone MG,Vázquez C,Savoy N,Giunta DH,Pérez LG,Sánchez MDL,Gamarnik AV,Ojeda DS,Santoro DM,Camino PJ,Antelo S,Rainero K,Vidiella GP,Miyazaki EA,Cornistein W,Trabadelo OA,Ross FM,Spotti M,Funtowicz G,Scordo WE,Losso MH,Ferniot I,Pardo PE,Rodriguez E,Rucci P,Pasquali J,Fuentes NA,Esperatti M,Speroni GA,Nannini EC,Matteaccio A,Michelangelo HG,Follmann D,Lane HC,Belloso WH,PlasmAr Study Group., A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. The New England journal of medicine. 2021 Feb 18 [PubMed PMID: 33232588]
[114]
Li L,Zhang W,Hu Y,Tong X,Zheng S,Yang J,Kong Y,Ren L,Wei Q,Mei H,Hu C,Tao C,Yang R,Wang J,Yu Y,Guo Y,Wu X,Xu Z,Zeng L,Xiong N,Chen L,Wang J,Man N,Liu Y,Xu H,Deng E,Zhang X,Li C,Wang C,Su S,Zhang L,Wang J,Wu Y,Liu Z, Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020 Aug 4 [PubMed PMID: 32492084]
[115]
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ (Clinical research ed.). 2020 Nov 3 [PubMed PMID: 33144278]
[116]
Wibmer CK,Ayres F,Hermanus T,Madzivhandila M,Kgagudi P,Oosthuysen B,Lambson BE,de Oliveira T,Vermeulen M,van der Berg K,Rossouw T,Boswell M,Ueckermann V,Meiring S,von Gottberg A,Cohen C,Morris L,Bhiman JN,Moore PL, SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature medicine. 2021 Apr [PubMed PMID: 33654292]
[117]
Wang P,Nair MS,Liu L,Iketani S,Luo Y,Guo Y,Wang M,Yu J,Zhang B,Kwong PD,Graham BS,Mascola JR,Chang JY,Yin MT,Sobieszczyk M,Kyratsous CA,Shapiro L,Sheng Z,Huang Y,Ho DD, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 Mar 8 [PubMed PMID: 33684923]
[118]
Baum A,Ajithdoss D,Copin R,Zhou A,Lanza K,Negron N,Ni M,Wei Y,Mohammadi K,Musser B,Atwal GS,Oyejide A,Goez-Gazi Y,Dutton J,Clemmons E,Staples HM,Bartley C,Klaffke B,Alfson K,Gazi M,Gonzalez O,Dick E Jr,Carrion R Jr,Pessaint L,Porto M,Cook A,Brown R,Ali V,Greenhouse J,Taylor T,Andersen H,Lewis MG,Stahl N,Murphy AJ,Yancopoulos GD,Kyratsous CA, REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science (New York, N.Y.). 2020 Nov 27 [PubMed PMID: 33037066]
[119]
Weinreich DM,Sivapalasingam S,Norton T,Ali S,Gao H,Bhore R,Musser BJ,Soo Y,Rofail D,Im J,Perry C,Pan C,Hosain R,Mahmood A,Davis JD,Turner KC,Hooper AT,Hamilton JD,Baum A,Kyratsous CA,Kim Y,Cook A,Kampman W,Kohli A,Sachdeva Y,Graber X,Kowal B,DiCioccio T,Stahl N,Lipsich L,Braunstein N,Herman G,Yancopoulos GD,Trial Investigators., REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. The New England journal of medicine. 2021 Jan 21 [PubMed PMID: 33332778]
[120]
Gottlieb RL,Nirula A,Chen P,Boscia J,Heller B,Morris J,Huhn G,Cardona J,Mocherla B,Stosor V,Shawa I,Kumar P,Adams AC,Van Naarden J,Custer KL,Durante M,Oakley G,Schade AE,Holzer TR,Ebert PJ,Higgs RE,Kallewaard NL,Sabo J,Patel DR,Klekotka P,Shen L,Skovronsky DM, Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021 Feb 16 [PubMed PMID: 33475701]
[121]
Wang P,Nair MS,Liu L,Iketani S,Luo Y,Guo Y,Wang M,Yu J,Zhang B,Kwong PD,Graham BS,Mascola JR,Chang JY,Yin MT,Sobieszczyk M,Kyratsous CA,Shapiro L,Sheng Z,Huang Y,Ho DD, Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv : the preprint server for biology. 2021 Jan 26 [PubMed PMID: 33532778]
[122]
RECOVERY Collaborative Group.,Horby P,Lim WS,Emberson JR,Mafham M,Bell JL,Linsell L,Staplin N,Brightling C,Ustianowski A,Elmahi E,Prudon B,Green C,Felton T,Chadwick D,Rege K,Fegan C,Chappell LC,Faust SN,Jaki T,Jeffery K,Montgomery A,Rowan K,Juszczak E,Baillie JK,Haynes R,Landray MJ, Dexamethasone in Hospitalized Patients with Covid-19. The New England journal of medicine. 2021 Feb 25 [PubMed PMID: 32678530]
[123]
Yuen CK,Lam JY,Wong WM,Mak LF,Wang X,Chu H,Cai JP,Jin DY,To KK,Chan JF,Yuen KY,Kok KH, SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerging microbes & infections. 2020 Dec [PubMed PMID: 32529952]
[124]
Ranieri VM,Pettilä V,Karvonen MK,Jalkanen J,Nightingale P,Brealey D,Mancebo J,Ferrer R,Mercat A,Patroniti N,Quintel M,Vincent JL,Okkonen M,Meziani F,Bellani G,MacCallum N,Creteur J,Kluge S,Artigas-Raventos A,Maksimow M,Piippo I,Elima K,Jalkanen S,Jalkanen M,Bellingan G,INTEREST Study Group., Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA. 2020 Feb 17 [PubMed PMID: 32065831]
[125]
Monk PD,Marsden RJ,Tear VJ,Brookes J,Batten TN,Mankowski M,Gabbay FJ,Davies DE,Holgate ST,Ho LP,Clark T,Djukanovic R,Wilkinson TMA,Inhaled Interferon Beta COVID-19 Study Group., Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Respiratory medicine. 2021 Feb [PubMed PMID: 33189161]
[126]
Davoudi-Monfared E,Rahmani H,Khalili H,Hajiabdolbaghi M,Salehi M,Abbasian L,Kazemzadeh H,Yekaninejad MS, A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. Antimicrobial agents and chemotherapy. 2020 Aug 20 [PubMed PMID: 32661006]
[127]
Huet T,Beaussier H,Voisin O,Jouveshomme S,Dauriat G,Lazareth I,Sacco E,Naccache JM,Bézie Y,Laplanche S,Le Berre A,Le Pavec J,Salmeron S,Emmerich J,Mourad JJ,Chatellier G,Hayem G, Anakinra for severe forms of COVID-19: a cohort study. The Lancet. Rheumatology. 2020 Jul [PubMed PMID: 32835245]
[128]
Cellina M,Orsi M,Bombaci F,Sala M,Marino P,Oliva G, Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagnostic and interventional imaging. 2020 May [PubMed PMID: 32278585]
[129]
Michot JM,Albiges L,Chaput N,Saada V,Pommeret F,Griscelli F,Balleyguier C,Besse B,Marabelle A,Netzer F,Merad M,Robert C,Barlesi F,Gachot B,Stoclin A, Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Jul [PubMed PMID: 32247642]
[130]
Rosas IO,Bräu N,Waters M,Go RC,Hunter BD,Bhagani S,Skiest D,Aziz MS,Cooper N,Douglas IS,Savic S,Youngstein T,Del Sorbo L,Cubillo Gracian A,De La Zerda DJ,Ustianowski A,Bao M,Dimonaco S,Graham E,Matharu B,Spotswood H,Tsai L,Malhotra A, Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. The New England journal of medicine. 2021 Feb 25 [PubMed PMID: 33631066]
[131]
Stone JH,Frigault MJ,Serling-Boyd NJ,Fernandes AD,Harvey L,Foulkes AS,Horick NK,Healy BC,Shah R,Bensaci AM,Woolley AE,Nikiforow S,Lin N,Sagar M,Schrager H,Huckins DS,Axelrod M,Pincus MD,Fleisher J,Sacks CA,Dougan M,North CM,Halvorsen YD,Thurber TK,Dagher Z,Scherer A,Wallwork RS,Kim AY,Schoenfeld S,Sen P,Neilan TG,Perugino CA,Unizony SH,Collier DS,Matza MA,Yinh JM,Bowman KA,Meyerowitz E,Zafar A,Drobni ZD,Bolster MB,Kohler M,D'Silva KM,Dau J,Lockwood MM,Cubbison C,Weber BN,Mansour MK,BACC Bay Tocilizumab Trial Investigators., Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. The New England journal of medicine. 2020 Dec 10 [PubMed PMID: 33085857]
[132]
REMAP-CAP Investigators.,Gordon AC,Mouncey PR,Al-Beidh F,Rowan KM,Nichol AD,Arabi YM,Annane D,Beane A,van Bentum-Puijk W,Berry LR,Bhimani Z,Bonten MJM,Bradbury CA,Brunkhorst FM,Buzgau A,Cheng AC,Detry MA,Duffy EJ,Estcourt LJ,Fitzgerald M,Goossens H,Haniffa R,Higgins AM,Hills TE,Horvat CM,Lamontagne F,Lawler PR,Leavis HL,Linstrum KM,Litton E,Lorenzi E,Marshall JC,Mayr FB,McAuley DF,McGlothlin A,McGuinness SP,McVerry BJ,Montgomery SK,Morpeth SC,Murthy S,Orr K,Parke RL,Parker JC,Patanwala AE,Pettilä V,Rademaker E,Santos MS,Saunders CT,Seymour CW,Shankar-Hari M,Sligl WI,Turgeon AF,Turner AM,van de Veerdonk FL,Zarychanski R,Green C,Lewis RJ,Angus DC,McArthur CJ,Berry S,Webb SA,Derde LPG, Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England journal of medicine. 2021 Feb 25 [PubMed PMID: 33631065]
[133]
Lescure FX,Honda H,Fowler RA,Lazar JS,Shi G,Wung P,Patel N,Hagino O,Sarilumab COVID-19 Global Study Group., Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine. 2021 Mar 4 [PubMed PMID: 33676590]
[134]
Richardson P,Griffin I,Tucker C,Smith D,Oechsle O,Phelan A,Rawling M,Savory E,Stebbing J, Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England). 2020 Feb 15 [PubMed PMID: 32032529]
[135]
Stebbing J,Phelan A,Griffin I,Tucker C,Oechsle O,Smith D,Richardson P, COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet. Infectious diseases. 2020 Apr [PubMed PMID: 32113509]
[136]
Kalil AC,Patterson TF,Mehta AK,Tomashek KM,Wolfe CR,Ghazaryan V,Marconi VC,Ruiz-Palacios GM,Hsieh L,Kline S,Tapson V,Iovine NM,Jain MK,Sweeney DA,El Sahly HM,Branche AR,Regalado Pineda J,Lye DC,Sandkovsky U,Luetkemeyer AF,Cohen SH,Finberg RW,Jackson PEH,Taiwo B,Paules CI,Arguinchona H,Erdmann N,Ahuja N,Frank M,Oh MD,Kim ES,Tan SY,Mularski RA,Nielsen H,Ponce PO,Taylor BS,Larson L,Rouphael NG,Saklawi Y,Cantos VD,Ko ER,Engemann JJ,Amin AN,Watanabe M,Billings J,Elie MC,Davey RT,Burgess TH,Ferreira J,Green M,Makowski M,Cardoso A,de Bono S,Bonnett T,Proschan M,Deye GA,Dempsey W,Nayak SU,Dodd LE,Beigel JH,ACTT-2 Study Group Members., Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. The New England journal of medicine. 2021 Mar 4 [PubMed PMID: 33306283]
[137]
Cao Y,Wei J,Zou L,Jiang T,Wang G,Chen L,Huang L,Meng F,Huang L,Wang N,Zhou X,Luo H,Mao Z,Chen X,Xie J,Liu J,Cheng H,Zhao J,Huang G,Wang W,Zhou J, Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. The Journal of allergy and clinical immunology. 2020 Jul [PubMed PMID: 32470486]
[138]
Roschewski M,Lionakis MS,Sharman JP,Roswarski J,Goy A,Monticelli MA,Roshon M,Wrzesinski SH,Desai JV,Zarakas MA,Collen J,Rose K,Hamdy A,Izumi R,Wright GW,Chung KK,Baselga J,Staudt LM,Wilson WH, Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science immunology. 2020 Jun 5 [PubMed PMID: 32503877]
[139]
Ni YN,Luo J,Yu H,Liu D,Liang BM,Liang ZA, The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis. The American journal of emergency medicine. 2018 Feb [PubMed PMID: 28780231]
[140]
Hui DS,Chow BK,Lo T,Tsang OTY,Ko FW,Ng SS,Gin T,Chan MTV, Exhaled air dispersion during high-flow nasal cannula therapy {i}versus{/i} CPAP {i}via{/i} different masks. The European respiratory journal. 2019 Apr; [PubMed PMID: 30705129]
[141]
Grieco DL,Menga LS,Cesarano M,Rosà T,Spadaro S,Bitondo MM,Montomoli J,Falò G,Tonetti T,Cutuli SL,Pintaudi G,Tanzarella ES,Piervincenzi E,Bongiovanni F,Dell'Anna AM,Delle Cese L,Berardi C,Carelli S,Bocci MG,Montini L,Bello G,Natalini D,De Pascale G,Velardo M,Volta CA,Ranieri VM,Conti G,Maggiore SM,Antonelli M,COVID-ICU Gemelli Study Group., Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial. JAMA. 2021 May 4 [PubMed PMID: 33764378]
[143]
Cook TM,El-Boghdadly K,McGuire B,McNarry AF,Patel A,Higgs A, Consensus guidelines for managing the airway in patients with COVID-19: Guidelines from the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetists. Anaesthesia. 2020 Jun [PubMed PMID: 32221970]
[144]
Alhazzani W,Møller MH,Arabi YM,Loeb M,Gong MN,Fan E,Oczkowski S,Levy MM,Derde L,Dzierba A,Du B,Aboodi M,Wunsch H,Cecconi M,Koh Y,Chertow DS,Maitland K,Alshamsi F,Belley-Cote E,Greco M,Laundy M,Morgan JS,Kesecioglu J,McGeer A,Mermel L,Mammen MJ,Alexander PE,Arrington A,Centofanti JE,Citerio G,Baw B,Memish ZA,Hammond N,Hayden FG,Evans L,Rhodes A, Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Critical care medicine. 2020 Jun [PubMed PMID: 32224769]
[145]
Polack FP,Thomas SJ,Kitchin N,Absalon J,Gurtman A,Lockhart S,Perez JL,Pérez Marc G,Moreira ED,Zerbini C,Bailey R,Swanson KA,Roychoudhury S,Koury K,Li P,Kalina WV,Cooper D,Frenck RW Jr,Hammitt LL,Türeci Ö,Nell H,Schaefer A,Ünal S,Tresnan DB,Mather S,Dormitzer PR,Şahin U,Jansen KU,Gruber WC,C4591001 Clinical Trial Group., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England journal of medicine. 2020 Dec 31 [PubMed PMID: 33301246]
[146]
Baden LR,El Sahly HM,Essink B,Kotloff K,Frey S,Novak R,Diemert D,Spector SA,Rouphael N,Creech CB,McGettigan J,Khetan S,Segall N,Solis J,Brosz A,Fierro C,Schwartz H,Neuzil K,Corey L,Gilbert P,Janes H,Follmann D,Marovich M,Mascola J,Polakowski L,Ledgerwood J,Graham BS,Bennett H,Pajon R,Knightly C,Leav B,Deng W,Zhou H,Han S,Ivarsson M,Miller J,Zaks T,COVE Study Group., Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine. 2021 Feb 4 [PubMed PMID: 33378609]
[147]
Sadoff J,Gray G,Vandebosch A,Cárdenas V,Shukarev G,Grinsztejn B,Goepfert PA,Truyers C,Fennema H,Spiessens B,Offergeld K,Scheper G,Taylor KL,Robb ML,Treanor J,Barouch DH,Stoddard J,Ryser MF,Marovich MA,Neuzil KM,Corey L,Cauwenberghs N,Tanner T,Hardt K,Ruiz-Guiñazú J,Le Gars M,Schuitemaker H,Van Hoof J,Struyf F,Douoguih M,ENSEMBLE Study Group., Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. The New England journal of medicine. 2021 Jun 10 [PubMed PMID: 33882225]
[148]
Voysey M,Clemens SAC,Madhi SA,Weckx LY,Folegatti PM,Aley PK,Angus B,Baillie VL,Barnabas SL,Bhorat QE,Bibi S,Briner C,Cicconi P,Collins AM,Colin-Jones R,Cutland CL,Darton TC,Dheda K,Duncan CJA,Emary KRW,Ewer KJ,Fairlie L,Faust SN,Feng S,Ferreira DM,Finn A,Goodman AL,Green CM,Green CA,Heath PT,Hill C,Hill H,Hirsch I,Hodgson SHC,Izu A,Jackson S,Jenkin D,Joe CCD,Kerridge S,Koen A,Kwatra G,Lazarus R,Lawrie AM,Lelliott A,Libri V,Lillie PJ,Mallory R,Mendes AVA,Milan EP,Minassian AM,McGregor A,Morrison H,Mujadidi YF,Nana A,O'Reilly PJ,Padayachee SD,Pittella A,Plested E,Pollock KM,Ramasamy MN,Rhead S,Schwarzbold AV,Singh N,Smith A,Song R,Snape MD,Sprinz E,Sutherland RK,Tarrant R,Thomson EC,Török ME,Toshner M,Turner DPJ,Vekemans J,Villafana TL,Watson MEE,Williams CJ,Douglas AD,Hill AVS,Lambe T,Gilbert SC,Pollard AJ,Oxford COVID Vaccine Trial Group., Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2021 Jan 9 [PubMed PMID: 33306989]
[149]
Shinde V,Bhikha S,Hoosain Z,Archary M,Bhorat Q,Fairlie L,Lalloo U,Masilela MSL,Moodley D,Hanley S,Fouche L,Louw C,Tameris M,Singh N,Goga A,Dheda K,Grobbelaar C,Kruger G,Carrim-Ganey N,Baillie V,de Oliveira T,Lombard Koen A,Lombaard JJ,Mngqibisa R,Bhorat AE,Benadé G,Lalloo N,Pitsi A,Vollgraaff PL,Luabeya A,Esmail A,Petrick FG,Oommen-Jose A,Foulkes S,Ahmed K,Thombrayil A,Fries L,Cloney-Clark S,Zhu M,Bennett C,Albert G,Faust E,Plested JS,Robertson A,Neal S,Cho I,Glenn GM,Dubovsky F,Madhi SA,2019nCoV-501 Study Group., Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. The New England journal of medicine. 2021 May 20; [PubMed PMID: 33951374]
[150]
Dunkle LM,Kotloff KL,Gay CL,Áñez G,Adelglass JM,Barrat Hernández AQ,Harper WL,Duncanson DM,McArthur MA,Florescu DF,McClelland RS,Garcia-Fragoso V,Riesenberg RA,Musante DB,Fried DL,Safirstein BE,McKenzie M,Jeanfreau RJ,Kingsley JK,Henderson JA,Lane DC,Ruíz-Palacios GM,Corey L,Neuzil KM,Coombs RW,Greninger AL,Hutter J,Ake JA,Smith K,Woo W,Cho I,Glenn GM,Dubovsky F,2019nCoV-301 Study Group., Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. The New England journal of medicine. 2021 Dec 15; [PubMed PMID: 34910859]
[151]
Aleem A,Nadeem AJ, Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) StatPearls. 2021 Jan [PubMed PMID: 34033367]
[152]
Goldberg Y,Mandel M,Bar-On YM,Bodenheimer O,Freedman L,Haas EJ,Milo R,Alroy-Preis S,Ash N,Huppert A, Waning Immunity after the BNT162b2 Vaccine in Israel. The New England journal of medicine. 2021 Dec 9; [PubMed PMID: 34706170]
[153]
Saiag E,Goldshmidt H,Sprecher E,Ben-Ami R,Bomze D, Immunogenicity of a BNT162b2 vaccine booster in health-care workers. The Lancet. Microbe. 2021 Dec; [PubMed PMID: 34661180]
[154]
Munro APS,Janani L,Cornelius V,Aley PK,Babbage G,Baxter D,Bula M,Cathie K,Chatterjee K,Dodd K,Enever Y,Gokani K,Goodman AL,Green CA,Harndahl L,Haughney J,Hicks A,van der Klaauw AA,Kwok J,Lambe T,Libri V,Llewelyn MJ,McGregor AC,Minassian AM,Moore P,Mughal M,Mujadidi YF,Murira J,Osanlou O,Osanlou R,Owens DR,Pacurar M,Palfreeman A,Pan D,Rampling T,Regan K,Saich S,Salkeld J,Saralaya D,Sharma S,Sheridan R,Sturdy A,Thomson EC,Todd S,Twelves C,Read RC,Charlton S,Hallis B,Ramsay M,Andrews N,Nguyen-Van-Tam JS,Snape MD,Liu X,Faust SN,COV-BOOST study group., Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet (London, England). 2021 Dec 18; [PubMed PMID: 34863358]
[155]
Abu-Raddad LJ,Chemaitelly H,Butt AA,National Study Group for COVID-19 Vaccination., Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. The New England journal of medicine. 2021 Jul 8 [PubMed PMID: 33951357]
[156]
Liu Y,Liu J,Xia H,Zhang X,Fontes-Garfias CR,Swanson KA,Cai H,Sarkar R,Chen W,Cutler M,Cooper D,Weaver SC,Muik A,Sahin U,Jansen KU,Xie X,Dormitzer PR,Shi PY, Neutralizing Activity of BNT162b2-Elicited Serum. The New England journal of medicine. 2021 Mar 8 [PubMed PMID: 33684280]
[157]
Lopez Bernal J,Gower C,Andrews N,Public Health England Delta Variant Vaccine Effectiveness Study Group., Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. The New England journal of medicine. 2021 Dec 16; [PubMed PMID: 34758250]
[158]
Lu L,Mok BW,Chen LL,Chan JM,Tsang OT,Lam BH,Chuang VW,Chu AW,Chan WM,Ip JD,Chan BP,Zhang R,Yip CC,Cheng VC,Chan KH,Jin DY,Hung IF,Yuen KY,Chen H,To KK, Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Dec 16; [PubMed PMID: 34915551]
[159]
Collie S,Champion J,Moultrie H,Bekker LG,Gray G, Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. The New England journal of medicine. 2021 Dec 29; [PubMed PMID: 34965358]
[160]
Bruxvoort KJ,Sy LS,Qian L,Ackerson BK,Luo Y,Lee GS,Tian Y,Florea A,Aragones M,Tubert JE,Takhar HS,Ku JH,Paila YD,Talarico CA,Tseng HF, Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ (Clinical research ed.). 2021 Dec 15; [PubMed PMID: 34911691]
[161]
Abdool Karim SS,de Oliveira T, New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. The New England journal of medicine. 2021 Mar 24 [PubMed PMID: 33761203]
[162]
Emary KRW,Golubchik T,Aley PK,Ariani CV,Angus B,Bibi S,Blane B,Bonsall D,Cicconi P,Charlton S,Clutterbuck EA,Collins AM,Cox T,Darton TC,Dold C,Douglas AD,Duncan CJA,Ewer KJ,Flaxman AL,Faust SN,Ferreira DM,Feng S,Finn A,Folegatti PM,Fuskova M,Galiza E,Goodman AL,Green CM,Green CA,Greenland M,Hallis B,Heath PT,Hay J,Hill HC,Jenkin D,Kerridge S,Lazarus R,Libri V,Lillie PJ,Ludden C,Marchevsky NG,Minassian AM,McGregor AC,Mujadidi YF,Phillips DJ,Plested E,Pollock KM,Robinson H,Smith A,Song R,Snape MD,Sutherland RK,Thomson EC,Toshner M,Turner DPJ,Vekemans J,Villafana TL,Williams CJ,Hill AVS,Lambe T,Gilbert SC,Voysey M,Ramasamy MN,Pollard AJ,COVID-19 Genomics UK consortium.,AMPHEUS Project.,Oxford COVID-19 Vaccine Trial Group., Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet (London, England). 2021 Apr 10 [PubMed PMID: 33798499]
[163]
COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators., Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive care medicine. 2021 Jan [PubMed PMID: 33211135]
[164]
Kaafarani HMA,El Moheb M,Hwabejire JO,Naar L,Christensen MA,Breen K,Gaitanidis A,Alser O,Mashbari H,Bankhead-Kendall B,Mokhtari A,Maurer L,Kapoen C,Langeveld K,El Hechi MW,Lee J,Mendoza AE,Saillant NN,Parks J,Fawley J,King DR,Fagenholz PJ,Velmahos GC, Gastrointestinal Complications in Critically Ill Patients With COVID-19. Annals of surgery. 2020 Aug [PubMed PMID: 32675498]
[165]
Zhou X,Cheng Z,Luo L,Zhu Y,Lin W,Ming Z,Chen W,Hu Y, Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thrombosis research. 2021 Feb 17 [PubMed PMID: 33631519]
[166]
Huang C,Huang L,Wang Y,Li X,Ren L,Gu X,Kang L,Guo L,Liu M,Zhou X,Luo J,Huang Z,Tu S,Zhao Y,Chen L,Xu D,Li Y,Li C,Peng L,Li Y,Xie W,Cui D,Shang L,Fan G,Xu J,Wang G,Wang Y,Zhong J,Wang C,Wang J,Zhang D,Cao B, 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England). 2021 Jan 16 [PubMed PMID: 33428867]
[167]
Taquet M,Geddes JR,Husain M,Luciano S,Harrison PJ, 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The lancet. Psychiatry. 2021 Apr 1 [PubMed PMID: 33836148]